{"id":42008,"date":"2025-06-10T18:30:11","date_gmt":"2025-06-10T13:00:11","guid":{"rendered":"https:\/\/matribhumisamachar.com\/en\/2025\/06\/10\/tevard-biosciences-names-dr-elisabeth-gardiner-chief-scientific-officer-to-lead-next-phase-of-trna-based-therapies\/"},"modified":"2025-06-10T18:30:11","modified_gmt":"2025-06-10T13:00:11","slug":"tevard-biosciences-names-dr-elisabeth-gardiner-chief-scientific-officer-to-lead-next-phase-of-trna-based-therapies","status":"publish","type":"post","link":"https:\/\/matribhumisamachar.com\/en\/2025\/06\/10\/tevard-biosciences-names-dr-elisabeth-gardiner-chief-scientific-officer-to-lead-next-phase-of-trna-based-therapies\/","title":{"rendered":"Tevard Biosciences Names Dr. Elisabeth Gardiner Chief Scientific Officer to Lead Next Phase of tRNA-Based Therapies"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/api.newsfilecorp.com\/newsinfo\/255057\/511\" width=\"2\" height=\"2\"><\/p>\n<p>Boston, Massachusetts&#8211;(Newsfile Corp. &#8211; June 10, 2025) &#8211; Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, today announced the      appointment of Elisabeth Gardiner, Ph.D., as Chief Scientific Officer. With more than 25 years of leadership in drug discovery and development across the biotech and pharmaceutical sectors, Dr.      Gardiner brings deep translational expertise that will accelerate Tevard&#8217;s mission to develop effective and durable tRNA-based therapies targeting the root cause of disease. As CSO, she will      lead scientific strategy and R&amp;D operations to expand Tevard&#8217;s novel platform of engineered suppressor tRNAs, which recently demonstrated the first sustained restoration of full-length      dystrophin in a Duchenne Muscular Dystrophy (DMD) model.    <\/p>\n<p>      To view the full announcement, including downloadable images, bios, and more, <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/DZjbNHXx8g\">click here<\/a>.    <\/p>\n<p>      <b>Key Takeaways:<\/b>    <\/p>\n<ul>\n<li>Dr. Gardiner&#8217;s experience scaling discovery and translational programs will be critical as Tevard advances their lead program toward the clinic and expands their pipeline across additional      indications.      <\/li>\n<li>Tevard Biosciences is working to unlock the potential of tRNA-based therapies. The company&#8217;s programs are based on its novel Suppressor tRNA technology platform that uses a viral vector to      insert the normal amino acid at the site of the premature stop codon.      <\/li>\n<li>Tevard&#8217;s lead program targeting TTN-related dilated cardiomyopathy is advancing rapidly, with new data expected in the near future.      <\/li>\n<\/ul>\n<p>      <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/rvko3Hr7WX\"><img decoding=\"async\" src=\"https:\/\/images.newsfilecorp.com\/files\/7294\/255057_figure1_550.jpg\" alt=\"Cannot view this image? Visit: https:\/\/images.newsfilecorp.com\/files\/7294\/255057_figure1_550.jpg\"><\/a>    <\/p>\n<p>      <i>Click image above to view full announcement.<\/i>    <\/p>\n<hr>\n<p>      <strong>About Tevard Biosciences\u00a0<\/strong><br \/>Tevard Biosciences is pioneering tRNA-based and other mRNA-modulating therapies to cure a broad range of genetic diseases. The privately held      biotechnology company was founded by renowned scientists along with life science executives and entrepreneurs who are also fathers of children with rare diseases. Tevard is advancing the use of      its novel suppressor tRNA platform in heart disease, muscular dystrophies, and neurological disorders. For more information, please visit <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/V7NbOIeJ74\">www.tevard.com<\/a>.    <\/p>\n<div>\n<p>      <b>Contacts:<\/b>    <\/p>\n<p>      Michelle Linn<br \/>      <a href=\"mailto:michelle@linndencom.com\">michelle@linndencom.com<\/a>    <\/p>\n<\/div>\n<p>      Source: <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/zEKRgso2nV\">Tevard<\/a>    <\/p>\n<p>      To view the source version of this press release, please visit <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/4QOPoCP8oP\">https:\/\/www.newsfilecorp.com\/release\/255057<\/a>    <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, Massachusetts&#8211;(Newsfile Corp. &#8211; June 10, 2025) &#8211; Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, today announced the appointment of Elisabeth Gardiner, Ph.D., as Chief Scientific Officer. With more than 25 years of leadership in drug discovery and development across the biotech and &hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[130],"tags":[],"class_list":["post-42008","post","type-post","status-publish","format-standard","","category-international"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.8.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Tevard Biosciences Names Dr. Elisabeth Gardiner Chief Scientific Officer to Lead Next Phase of tRNA-Based Therapies - Matribhumi Samachar English<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/matribhumisamachar.com\/en\/2025\/06\/10\/tevard-biosciences-names-dr-elisabeth-gardiner-chief-scientific-officer-to-lead-next-phase-of-trna-based-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tevard Biosciences Names Dr. Elisabeth Gardiner Chief Scientific Officer to Lead Next Phase of tRNA-Based Therapies - Matribhumi Samachar English\" \/>\n<meta property=\"og:description\" content=\"Boston, Massachusetts&#8211;(Newsfile Corp. &#8211; June 10, 2025) &#8211; Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, today announced the appointment of Elisabeth Gardiner, Ph.D., as Chief Scientific Officer. With more than 25 years of leadership in drug discovery and development across the biotech and &hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/matribhumisamachar.com\/en\/2025\/06\/10\/tevard-biosciences-names-dr-elisabeth-gardiner-chief-scientific-officer-to-lead-next-phase-of-trna-based-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"Matribhumi Samachar English\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-10T13:00:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/api.newsfilecorp.com\/newsinfo\/255057\/511\" \/>\n<meta name=\"author\" content=\"Saransh Kanaujia\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Saransh Kanaujia\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/2025\/06\/10\/tevard-biosciences-names-dr-elisabeth-gardiner-chief-scientific-officer-to-lead-next-phase-of-trna-based-therapies\/\",\"url\":\"https:\/\/matribhumisamachar.com\/en\/2025\/06\/10\/tevard-biosciences-names-dr-elisabeth-gardiner-chief-scientific-officer-to-lead-next-phase-of-trna-based-therapies\/\",\"name\":\"Tevard Biosciences Names Dr. Elisabeth Gardiner Chief Scientific Officer to Lead Next Phase of tRNA-Based Therapies - Matribhumi Samachar English\",\"isPartOf\":{\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#website\"},\"datePublished\":\"2025-06-10T13:00:11+00:00\",\"dateModified\":\"2025-06-10T13:00:11+00:00\",\"author\":{\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1\"},\"breadcrumb\":{\"@id\":\"https:\/\/matribhumisamachar.com\/en\/2025\/06\/10\/tevard-biosciences-names-dr-elisabeth-gardiner-chief-scientific-officer-to-lead-next-phase-of-trna-based-therapies\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/matribhumisamachar.com\/en\/2025\/06\/10\/tevard-biosciences-names-dr-elisabeth-gardiner-chief-scientific-officer-to-lead-next-phase-of-trna-based-therapies\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/2025\/06\/10\/tevard-biosciences-names-dr-elisabeth-gardiner-chief-scientific-officer-to-lead-next-phase-of-trna-based-therapies\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/matribhumisamachar.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tevard Biosciences Names Dr. Elisabeth Gardiner Chief Scientific Officer to Lead Next Phase of tRNA-Based Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#website\",\"url\":\"https:\/\/matribhumisamachar.com\/en\/\",\"name\":\"Matribhumi Samachar English\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/matribhumisamachar.com\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1\",\"name\":\"Saransh Kanaujia\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g\",\"caption\":\"Saransh Kanaujia\"},\"description\":\"Saransh Kanaujia is currently editor of Matribhumi Samachar Group. He earlier worked with Hindusthan Samachar News Agency. He is also associated with many organizations.\",\"sameAs\":[\"https:\/\/matribhumisamachar.com\/en\"],\"url\":\"https:\/\/matribhumisamachar.com\/en\/author\/matribhumisamachar\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tevard Biosciences Names Dr. Elisabeth Gardiner Chief Scientific Officer to Lead Next Phase of tRNA-Based Therapies - Matribhumi Samachar English","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/matribhumisamachar.com\/en\/2025\/06\/10\/tevard-biosciences-names-dr-elisabeth-gardiner-chief-scientific-officer-to-lead-next-phase-of-trna-based-therapies\/","og_locale":"en_US","og_type":"article","og_title":"Tevard Biosciences Names Dr. Elisabeth Gardiner Chief Scientific Officer to Lead Next Phase of tRNA-Based Therapies - Matribhumi Samachar English","og_description":"Boston, Massachusetts&#8211;(Newsfile Corp. &#8211; June 10, 2025) &#8211; Tevard Biosciences, Inc., a privately held biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, today announced the appointment of Elisabeth Gardiner, Ph.D., as Chief Scientific Officer. With more than 25 years of leadership in drug discovery and development across the biotech and &hellip;","og_url":"https:\/\/matribhumisamachar.com\/en\/2025\/06\/10\/tevard-biosciences-names-dr-elisabeth-gardiner-chief-scientific-officer-to-lead-next-phase-of-trna-based-therapies\/","og_site_name":"Matribhumi Samachar English","article_published_time":"2025-06-10T13:00:11+00:00","og_image":[{"url":"https:\/\/api.newsfilecorp.com\/newsinfo\/255057\/511"}],"author":"Saransh Kanaujia","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Saransh Kanaujia","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/matribhumisamachar.com\/en\/2025\/06\/10\/tevard-biosciences-names-dr-elisabeth-gardiner-chief-scientific-officer-to-lead-next-phase-of-trna-based-therapies\/","url":"https:\/\/matribhumisamachar.com\/en\/2025\/06\/10\/tevard-biosciences-names-dr-elisabeth-gardiner-chief-scientific-officer-to-lead-next-phase-of-trna-based-therapies\/","name":"Tevard Biosciences Names Dr. Elisabeth Gardiner Chief Scientific Officer to Lead Next Phase of tRNA-Based Therapies - Matribhumi Samachar English","isPartOf":{"@id":"https:\/\/matribhumisamachar.com\/en\/#website"},"datePublished":"2025-06-10T13:00:11+00:00","dateModified":"2025-06-10T13:00:11+00:00","author":{"@id":"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1"},"breadcrumb":{"@id":"https:\/\/matribhumisamachar.com\/en\/2025\/06\/10\/tevard-biosciences-names-dr-elisabeth-gardiner-chief-scientific-officer-to-lead-next-phase-of-trna-based-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/matribhumisamachar.com\/en\/2025\/06\/10\/tevard-biosciences-names-dr-elisabeth-gardiner-chief-scientific-officer-to-lead-next-phase-of-trna-based-therapies\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/matribhumisamachar.com\/en\/2025\/06\/10\/tevard-biosciences-names-dr-elisabeth-gardiner-chief-scientific-officer-to-lead-next-phase-of-trna-based-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/matribhumisamachar.com\/en\/"},{"@type":"ListItem","position":2,"name":"Tevard Biosciences Names Dr. Elisabeth Gardiner Chief Scientific Officer to Lead Next Phase of tRNA-Based Therapies"}]},{"@type":"WebSite","@id":"https:\/\/matribhumisamachar.com\/en\/#website","url":"https:\/\/matribhumisamachar.com\/en\/","name":"Matribhumi Samachar English","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/matribhumisamachar.com\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1","name":"Saransh Kanaujia","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g","caption":"Saransh Kanaujia"},"description":"Saransh Kanaujia is currently editor of Matribhumi Samachar Group. He earlier worked with Hindusthan Samachar News Agency. He is also associated with many organizations.","sameAs":["https:\/\/matribhumisamachar.com\/en"],"url":"https:\/\/matribhumisamachar.com\/en\/author\/matribhumisamachar\/"}]}},"_links":{"self":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/42008","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/comments?post=42008"}],"version-history":[{"count":0,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/42008\/revisions"}],"wp:attachment":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/media?parent=42008"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/categories?post=42008"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/tags?post=42008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}